Helix Receives Approval To Open Sites In Germany For Its Ongoing Clinical Trial With Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
Helix Receives Approval To Open Sites In Germany For Its Ongoing Clinical Trial With Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
Helix BioPharma announced that it has received the necessary regulatory approvals to open clinical sites in Germany to expand upon its clinical trial with Topical Interferon Alpha-2b in patients with ano-genital warts, which is presently underway in Sweden. "We are pleased to have received approval to open these additional clinical sites," said John Docherty, President of Helix BioPharma.
What next?
Posting Komentar